The Start of the First-Ever ADNP Clinical Trial Marks Historic Moment in ADNP Research History!
Researchers at the Gozes Lab have identified a potential drug treatment for children with ADNP, called CP201/NAP.  For the first time, we have in front of us a possible treatment for children with ADNP Syndrome. 2017 marks the initiation of the clinical trial of CP201/NAP for ADNP Syndrome. 

RECRUITMENT FOR THIS TRIAL HAS NOT YET BEGUN
Coronis NeuroSciences  is a specialty pharma company focused on the development of Innovative therapies for Neurocognitive and Neurodegenerative disorders. 

Coronis’ pipeline currently includes an innovative drug for major for ADNP Syndrome and is in the pre-clinical stage.  CP201 is the Coronis' leading drug and is developed to treat ADNP-Related Syndrome. 

HOME. ABOUT. RESEARCH. SUPPORT-US. PRIVACY-POLICY. ADNP SYNDROME. ADNP GENE. SYNDROME PHENOTYPE.


All rights reserved. No portion of the content of this website may be reproduced in any manner without the written permission of the author/creator.   Any information used from this website must also have credit noted to ADNP Kids Research Foundation / www.adnpfoundation.org. The information on this website is not substitute for personal diagnosis or medical care advise. Families and patients should consult a medically qualified clinician in all matters relating to genetic diagnosis, management and health. Information on ADNP changes is a very fast-moving field and while the information in this guide is believed to be the best available at the time of publication, some facts may later be updated or change. Please see additional disclosures on our PRIVACY POLICY page.